Skip to main content
Caplight Logo









Obulytix

Obulytix

Private
BelgiumHealthcare & Life Scienceshttps://www.obulytix.com/

Last Round

Seed

Dec 5, 2023

Total Funding Raised

$4.33M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Obulytix is a biotechnology company developing a novel class of precision biologics designed to selectively target and eliminate drug-resistant bacterial pathogens.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Government Contracts, Services & Consulting

AI Layer

Application

Keywords

lysin therapeuticsantimicrobial resistanceAMRphage lysinsenzyme-based antibioticsenzybioticsAI drug discoveryprecision biologicssynthetic biologymicrobiome sparingGram-negative bacteriadrug discovery platformphage therapysuperbug crisisAcinetobacter baumannii

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Obulytix Comparables

Compare Obulytix with similar companies based on industry and business-model similarity.

Obulytix comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Telum Therapeutics
85%
GangaGen
78%
PrecisioBiotix Therapeutics
76%

Obulytix Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedDec 5, 2023

Key People

Founding team and executive leadership

Kristof Van Emelen

Chief Executive Officer

Executive Team

Sara Lambrechts

Chief Financial Officer

Executive Team

Obulytix Investors

Notable investors and investment history

Obulytix investors
InvestorRounds
Boehringer Ingelheim Venture FundSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 25, 2026

    Monthly visitors increased 128% MoM.

  • Feb 17, 2026

    Grew 21% QoQ from 14 to 17 employees.

Obulytix Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Obulytix Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Obulytix's valuation, stock price, and market status.

Firmographic Details

HeadquartersBelgium
Employee Range19
Year Founded2023
Last FundingDec 5, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?